Buy Ascorbic acid with glucose pills 100 mg 10 pcs
  • Buy Ascorbic acid with glucose pills 100 mg 10 pcs

Ascorbic Acid, Dextrose

Pharmstandard Ufavita
1442 Items
2019-09-19
Dosage form
Brand & Manufacturer
Package Size
$12.60
Quantity
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Ascorbic acid has a metabolic effect, is involved in the regulation of redox processes, carbohydrate metabolism, blood clotting, tissue regeneration, in the synthesis of steroid hormones; increases the body's resistance to infections, reduces vascular permeability, reduces the need for vitamins B1A b2, A, E, folic acid, pantothenic acid.

Indications

  • hypo-and avitaminosis C;
  • increased need for ascorbic acid (the period of intensive growth, pregnancy, lactation, increased physical activity, the period of convalescence).

Composition

1 tablet contains ascorbic acid 100 mg; dextrose 877 mg.

No customer reviews for the moment.

Write your review

Write your review

Ascorbic Acid, Dextrose

Dosage and Administration

The drug is intended for use in the oral cavity and can be administered only in

tissues where there is no inflammation.

Injection into inflamed tissue is not allowed.

The drug can not be administered intravenously.

In order to avoid accidental ingestion of the drug in the blood vessels, before

its introduction should always be carried out aspiration test (in two stages).

Major systemic reactions that may develop as a result of random

intravascular administration of the drug can be avoided by following the injection technique:

after the aspiration test, 0.1-0.2 ml of the drug is slowly injected, then, not

earlier than 20-30 seconds, slowly inject the rest of the dose. Pressure

injections should match the sensitivity of the tissue.

For anesthesia with uncomplicated removal of the teeth of the upper jaw in the absence of

inflammation is usually sufficient to create a depot of the drug in the area of ​​the transition fold

by introducing it into the submucosa from the vestibular side (1.7 ml of the drug per

tooth). In rare cases, complete anesthesia may be required.

additional administration from 1 ml to 1.7 ml. In most cases, this allows not

carry out painful palatal injections. When deleting several near

placed teeth, it is usually possible to limit the number of injections.

For anesthesia with cuts and suturing in the palate to create the palatine

A depot requires about 0.1 ml of the drug per injection.

In the case of removal of premolars of the lower jaw, in the absence of inflammation,

do without mandibular anesthesia, as is usually sufficient

infiltration anesthesia provided by the injection of 1.7 ml per tooth. If so

by not achieving the desired effect, additional

injection of 1-1.7 ml of anesthetic into the submucosa in the region of the transitional fold of the lower

jaws from the vestibular side. If in this case it was not possible to achieve complete

anesthesia, it is necessary to conduct a conductive blockade of the mandibular nerve.

6

When processing cavities and grinding teeth under the crowns, with the exception of the lower

molars, depending on the volume and duration of treatment is shown

the introduction of the drug Certacainum 40 mg / ml + 0.005 mg / ml in the transition fold region with

vestibular side in a dose of 0.5-1.7 ml per tooth.

During surgery, the drug Certacainum 40 mg / ml + 0.01 mg / ml in

Depending on the severity and duration of the intervention is dosed individually.

When performing a single medical procedure, adults can enter Articaine in a dose up to

7 mg per 1 kg of body weight. Patients were well tolerated in doses up to 500 mg.

(corresponds to 12.5 ml of solution for injection).

For pediatric patients (over 4 years old), minimal doses should be applied,

necessary to achieve adequate anesthesia, the dose of the drug Certacain

is selected depending on the age and body weight of the child, but the dose of articaine is not

should exceed 7 mg per 1 kg of body weight (0.175 ml / kg). Use of the drug in children

younger than 1 year has not been studied.

For elderly patients and all patients with severe renal and hepatic

insufficiency may create elevated plasma concentrations

Articaine. For these patients, the minimum dose required for

achieve sufficient depth of anesthesia

Adverse reactions

The frequency of side effects is presented in accordance with the classification,

recommended by the World Health Organization:

very often (≥ 1/10);

often (≥ 1/100, <1/10);

infrequently (≥ 1/1000, <1/100);

rarely (≥ 1/10000, <1/1000);

very rarely (<1/10000), including individual messages;

frequency is unknown (according to the available data, determine the frequency of occurrence

seems possible).

Nervous system disorders

Often: paresthesia, hypesthesia; headache mainly due to

composition of the drug epinephrine.

Infrequently: dizziness.

Frequency unknown: dose-dependent reactions from the central nervous system:

7

agitation, nervousness, stupor, sometimes progressive to loss of consciousness, coma,

respiratory disorders, sometimes progressing to respiratory arrest, muscular

tremor, muscle twitching, sometimes progressive to generalized

seizures.

Sometimes in violation of the correct injection technique with the introduction

damage to local anesthetics in dental practice

facial nerve, which can lead to the development of facial paralysis.

Violations by the organ of vision

Frequency unknown: visual impairment (blurred vision,

mydriasis, blindness, double vision), usually reversible and occurring during or

shortly after injection of a local anesthetic.

Disorders of the gastrointestinal tract

Often: nausea, vomiting.

Violations of the heart and blood vessels

Infrequently: tachycardia, disturbance of a heart rhythm, increase in arterial pressure.

Frequency unknown: lower blood pressure, bradycardia, cardiac

failure and shock.

Immune system disorders

Frequency unknown: allergic reactions (swelling and inflammation at the injection site),

hyperemia of the skin, itching, conjunctivitis, rhinitis, angioedema (edema

upper and / or lower lips, cheeks, vocal cords swelling with a "lump in the throat",

difficulty swallowing, hives, difficulty breathing). Any of these manifestations

may progress to anaphylactic shock.

General disorders and disorders at the site of administration

Frequency unknown: occasional intravascular injection may result

zones of ischemia at the injection site, up to tissue necrosis.

Hypersensitivity to articaine or other local anesthetic

amide-type agents, epinephrine, sulfites (in particular, in patients suffering from

bronchial asthma with increased sensitivity to sulfites, as possible

acute allergic reactions with symptoms of anaphylactic shock, such as

bronchospasm), or to any other of the auxiliary components of the drug.

Contraindications due to the presence in the composition of the drug Articaine

- severe sinus dysfunction or severe conduction disorders

(for example, severe bradycardia, atrioventricular block II or III degree);

- acute decompensated heart failure;

- severe arterial hypotension.

Contraindications due to the presence in the composition of the drug epinephrine

- angle-closure glaucoma;

- hyperfunction of the thyroid gland;

- paroxysmal tachycardia, tachyarrhythmia;

- recent myocardial infarction (up to 6 months);

- recently transferred coronary artery bypass surgery (up to 3 months);

- taking non-selective beta-blockers, for example, propranolol (risk

hypertensive crisis and severe bradycardia);

- pheochromocytoma;

- severe form of arterial hypertension.

4

Carefully

- in patients with chronic heart failure, coronary artery disease

heart, angina, atherosclerosis, myocardial infarction in history, impaired

heart rhythm, hypertension;

- in patients with cerebrovascular disorders, history of stroke;

- in patients with chronic bronchitis, emphysema;

- in patients with diabetes mellitus (potential risk of changes in concentration

blood glucose);

- in patients with cholinesterase deficiency (use is possible only in the case of

absolutely necessary, since it is possible prolongation and a pronounced increase

drug action);

- in patients with bleeding disorders;

- in patients with severe violations of the liver and kidneys;

- in patients with marked arousal;

- in patients with epilepsy in history;

- when combined with halogen-containing agents when conducting

inhalation anesthesia

Drug interactions

Simultaneous use is contraindicated

With simultaneous use with non-cardio selective beta-blockers,

for example, propanolol, may develop hypertonic crisis and severe

bradycardia.

Simultaneous use is possible with caution.

The action of vasoconstrictors that increase blood pressure, for example,

epinephrine may be enhanced by tricyclic antidepressants or

monoamine oxidase inhibitors.

Local anesthetics enhance the effect of drugs

depressing the central nervous system. Narcotic analgesics increase

action of local anesthetics, however, increase the risk of respiratory depression.

When using the drug Tsertacain in patients taking heparin or

acetylsalicylic acid, may develop bleeding at the injection site.

With simultaneous use with cholinesterase inhibitors may slow down

metabolism of local anesthetics, resulting in possible

prolongation and pronounced enhancement of the action of Articaine.

Epinephrine can inhibit insulin release from pancreatic beta cells

glands and reduce the effects of hypoglycemic agents for oral administration.

Some means of inhalation anesthesia, such as halothane, may increase

myocardial sensitivity to catecholamines and increase the risk of developing disorders

heart rate after injection of the drug Certacain.

When processing the injection site of a local anesthetic with disinfectant solutions,

containing heavy metals, increases the risk of local reactions - edema,

soreness

Special instructions

Regional and local anesthesia should be performed by experienced professionals in

an appropriately equipped room with the availability of ready to

immediate use of equipment and preparations necessary for

monitoring of cardiac activity and resuscitation. Staff,

performing anesthesia must be qualified and trained

10

performing anesthesia, must be familiar with the diagnosis and treatment of systemic

toxic reactions, adverse events, reactions and other complications.

To prevent infection (including the hepatitis virus)

make sure that new solutions are always used when taking the solution from the ampoules

sterile syringes and needles.

In order to avoid the development of adverse reactions, it is necessary to apply minimal

effective doses of the drug and before the introduction of the drug to conduct a two-step

aspiration test (see the section "Route of Administration and Doses").

When using the drug may inadvertently injuring the lips, cheeks,

mucous membrane and tongue, especially in children, due to reduced sensitivity.

The patient should be warned that food is possible only after

termination of local anesthesia and recovery of sensitivity.

The drug is intended for use in dentistry. Use for anesthesia

distal extremities is unacceptable due to the risk of ischemia due to

epinephrine content.

Impact on the ability to drive vehicles and mechanisms

The possibility of admission of the patient to the management of vehicles and mechanisms

determined by a doctor.

Overdosage

Symptoms

The most common symptoms are cardiovascular reactions.

system and nervous system, nausea, motor restlessness, clouding of consciousness

during injection, respiratory disorders, muscle twitching, convulsions, shock.

Treatment

Symptomatic treatment. When first signs of overdose appear or

side effects such as nausea, motor restlessness, turbidity

consciousness during the injection, it should be interrupted, the patient transferred to the horizontal

position, clear airway, monitor heart rate and blood pressure.

It is recommended, even if the symptoms do not seem too severe, to ensure

intravenous access. For respiratory disorders, depending on the severity, give

oxygen, in some cases, conduct artificial respiration. Central

analeptics are contraindicated. Muscle twitching or generalized cramps

removed by intravenous injection of short or ultrashort barbiturates

actions. Falling blood pressure, tachycardia or bradycardia often

are eliminated when the patient is placed in a horizontal position. With severe

circulatory disorders and shock of any genesis after stopping the injection

emergency measures are shown: ensuring the airway (oxygen

insufflation), intravenous fluids (electrolyte solution),

glucocorticosteroids. Additionally, you can enter plasma substitutes, albumin.

With a threatening circulatory disorder and increasing bradycardia, it is administered from

0.25 ml to 1 ml epinephrine. An intravenous injection of epinephrine should be made.

slowly under the control of heart rate and blood pressure.

A single dose of intravenous injection of epinephrine should not exceed 0.1 mg, in

Further, if necessary, epinephrine can be administered dropwise (rate of infusion

through dropper is adjusted depending on the pulse rate and blood pressure).

Severe forms of tachycardia and tachyarrhythmias can be eliminated by using

antiarrhythmic drugs, but do not use non-selective beta

adrenergic blockers. Oxygen supply and blood circulation control are needed in

anyway. With an increase in blood pressure in patients suffering

9

hypertension, should, if necessary, apply peripheral

vasodilators

  • Brand name: Certacain
  • Active ingredient: Articaine, Epinephrine
  • Dosage form: Injection
  • Manufacturer: Graminexx

8 other products in the same category:

arrow_upward